ADRP Advisory Board Member Amanda Hess discusses advances in transfusion medicine, challenges blood centers face, and how ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

The Michael J. Fox Foundation for Parkinson’s Research has partnered with Grifols, a global healthcare company, to identify ...

Will fund a pilot study to analyze longitudinal plasma samples covering a period of up to 10 years.

Grifols has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based ...

The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the ...

Important milestone for Biotest: Biologics License Application for Fibrinogen submitted to the US Food and Drug Administration (FDA) Biotest's fibrinogen aims to fulfill a high unmet medical need for ...

PORTLAND, OR, UNITED STATES, January 6, 2025 /EINPresswire / -- The global immunoglobulin market is experiencing significant growth, driven by the increasing prevalence of immune-related diseases and ...

CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and ...

To make further advances, scientists are, however, focusing on another NIF milestone achieved in February of 2021 – burning plasma for the first time. In NIF’s approach to harnessing fusion ...

Immune globulin (human) is under clinical development by Grifols and currently in Phase II for Coronavirus Disease 2019 (COVID-19).